e-learning
resources
European Respiratory Review
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Endothelin: setting the scene in PAH
Dupuis J.
Source:
Eur Respir Rev 2008; 17: 3-7
Journal Issue:
August 2007 - 16 (102)
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dupuis J.. Endothelin: setting the scene in PAH. Eur Respir Rev 2008; 17: 3-7
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011
Single centre experience with endothelin receptor blockade in pulmonary hypertension
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Inhalation of endothelin receptor blockers in pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Bosentan therapy for portopulmonary hypertension
Source: Eur Respir J 2005; 25: 502-508
Year: 2005
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: 1007-1010
Year: 2004
Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Source: Eur Respir Rev 2009; 18: 253-259
Year: 2009
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 204s
Year: 2005
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept